NeoStem, Inc. Appoints Vice President of Sales and Marketing

NeoStem, Inc. Appoints Vice President of Sales and Marketing

NEW YORK, Oct. 5 NY-NeoStem-elects-VP

NEW YORK, Oct. 5 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has appointed Teresa Lepore, as the Company's Vice President, Sales and Marketing.

Teresa Lepore began serving as the Company's Vice President, Sales and Marketing on October 1, 2009. Since March 2005, she served as a Senior Vice President for PinnacleCare, a company engaged in Health Advisory Services. Teresa was responsible for establishing PinnacleCare's Northeast offices in early 2005. Teresa initiated member services, network development, business development as well as staff recruitment and development. Teresa has a diverse background in medical advisory services, disease management program development, community development, fundraising, marketing and non-profit administration. Prior to joining PinnacleCare, from March 2002 through June 2004 she was a Health Education Specialist for WellPoint Health Networks, a company engaged in Health Benefits where she designed disease management programs.

Teresa spent fifteen years in Non-Profit administration before moving into Health Information and Advisory Services. Her non profit background began in crisis intervention programs helping to establish shelters and programs advocating for victims of domestic violence, including Child and Elder abuse. Her responsibilities included the training and supervision of staff grant writing and general fundraising. In addition to direct client service organizations Teresa served as a Resource and Capitalization Coordinator for Common Wealth, Inc., where she was responsible for resource development activities, grant writing, fundraising, and marketing. She provided training and consulting services to community and grassroots groups in community organizing, grant writing, marketing, project planning and resource development. Teresa received a Bachelor of Science from Youngstown State University in 1997.

Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are extremely pleased to add Ms. Lepore to our management team at NeoStem. Her extensive experience and success in the high end concierge medical services industry will be critical for the roll out of our collection, processing and storage business in the US. Additionally, her not for profit background will allow us to focus more on assisting the Stem-for-Life Foundation grow to support autologous stem cell research and assist first responders in having their own stem cells collected."

About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. For more information, please visit: www.neostem.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.